Inozyme Pharma, Inc. (INZY)

NASDAQ: INZY · IEX Real-Time Price · USD
5.78
-0.04 (-0.69%)
Feb 20, 2024, 4:00 PM EST - Market closed
-0.69%
Market Cap 356.98M
Revenue (ttm) n/a
Net Income (ttm) -68.17M
Shares Out 61.76M
EPS (ttm) -1.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 563,564
Open 5.80
Previous Close 5.82
Day's Range 5.67 - 5.90
52-Week Range 2.51 - 7.33
Beta 1.30
Analysts Strong Buy
Price Target 15.00 (+159.52%)
Earnings Date Mar 20, 2024

About INZY

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 56
Stock Exchange NASDAQ
Ticker Symbol INZY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for INZY stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 159.52% from the latest price.

Price Target
$15.0
(159.52% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the tr...

14 days ago - GlobeNewsWire

Inozyme Pharma to Participate in Upcoming Investor Conferences

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for th...

3 months ago - GlobeNewsWire

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 –

3 months ago - GlobeNewsWire

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England's Generation Study of Rare Conditions

BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc.  (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for t...

4 months ago - GlobeNewsWire

Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc.  (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for t...

4 months ago - GlobeNewsWire

Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023

Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) Company to share interim data updates from ongoing Phase 1/2 t...

5 months ago - GlobeNewsWire

Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mi...

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inozyme Pharma, Inc. - INZY

NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY).  Such investors are advised ...

6 months ago - PRNewsWire

Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 –

7 months ago - GlobeNewsWire

Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min...

7 months ago - GlobeNewsWire

Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock

BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min...

7 months ago - GlobeNewsWire

Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock

BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min...

7 months ago - GlobeNewsWire

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients -

7 months ago - GlobeNewsWire

Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023

– Conference call and webcast to be held on July 26, 2023, at 8am ET – BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare...

7 months ago - GlobeNewsWire

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min...

8 months ago - GlobeNewsWire

Inozyme Pharma to Present at the Jefferies Healthcare Conference

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min...

9 months ago - GlobeNewsWire

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

- Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into the f...

10 months ago - GlobeNewsWire

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mi...

11 months ago - GlobeNewsWire

Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

BOSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic m...

11 months ago - GlobeNewsWire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer

BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mi...

11 months ago - GlobeNewsWire

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

- Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO -

11 months ago - GlobeNewsWire

Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mi...

1 year ago - GlobeNewsWire

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial -

1 year ago - GlobeNewsWire

Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023

- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE) –

1 year ago - GlobeNewsWire

Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 –

1 year ago - GlobeNewsWire